NASDAQ:GBT Global Blood Therapeutics (GBT) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free GBT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$68.49▼$68.4950-Day Range$68.07▼$68.4952-Week Range$21.65▼$73.02Volume74 shsAverage Volume2.07 million shsMarket Capitalization$4.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Global Blood Therapeutics alerts: Email Address Global Blood Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainability-1.95Upright™ Environmental ScoreNews Sentiment0.52Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.71) to ($3.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.14 out of 5 starsMedical Sector921st out of 939 stocksPharmaceutical Preparations Industry425th out of 434 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Global Blood Therapeutics. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GBT. Previous Next 0.0 Dividend Strength Dividend YieldGlobal Blood Therapeutics does not currently pay a dividend.Dividend GrowthGlobal Blood Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobal Blood Therapeutics has received a 54.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other hematological medication (B06)", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Global Blood Therapeutics is -1.95. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Global Blood Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for GBT on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Global Blood Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of Global Blood Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Global Blood Therapeutics are expected to grow in the coming year, from ($4.71) to ($3.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Global Blood Therapeutics is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Global Blood Therapeutics is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlobal Blood Therapeutics has a P/B Ratio of 22.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Global Blood Therapeutics Stock (NASDAQ:GBT)Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Read More Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here GBT Stock News HeadlinesMarch 25, 2024 | skift.comAmex GBT to Acquire CWT for $570 MillionMarch 22, 2024 | msn.comHow Dr. Ted Love, a cardiologist turned biotech executive, sold his sickle cell company to Pfizer for $5.4BMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…February 5, 2024 | forbes.comHow Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 BillionDecember 27, 2023 | msn.comUS biotech firm addresses critical gap in blood pressure managementDecember 20, 2023 | bbc.comShould we pay people for donating blood?November 13, 2023 | bizjournals.comA serial biotech company founder has Parkinson's. His latest company is targeting a potentially game-changing therapyNovember 8, 2023 | skift.comAmex GBT Sees More Small Companies Needing Business Travel HelpMarch 28, 2024 | DTI (Ad)CBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. November 8, 2023 | finance.yahoo.comGBT Technologies Cancels and Voids Reverse Stock SplitOctober 6, 2023 | finance.yahoo.comGlobal Peripheral Blood Mononuclear Cells Research Report 2023: R&D Revolution - PBMCs Paving the Way for Medical BreakthroughsSeptember 28, 2023 | benzinga.comDiabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This TrajectoryJuly 28, 2023 | finance.yahoo.comPFE Mar 2024 32.500 callJune 17, 2023 | benzinga.comGout Therapeutics Market Challenges, Drivers, Growth Opportunities, and Major Company Profiles 2023June 14, 2023 | finance.yahoo.comGlobal Patient Blood Management Market to Reach $23.6 Billion by 2030June 12, 2023 | finance.yahoo.comGlobal Lymphoma Therapeutics Market Report 2023: Sector is Expected to Reach $24.9 Billion by 2029 at a CAGR of 7.8%June 11, 2023 | finance.yahoo.comGlobal Health Study Validates Biospectal OptiBP Mobile Blood Pressure Measurement App Accuracy Across Diverse SettingsJune 7, 2023 | bizjournals.comTed Love, now the chair of biotech's big trade group, talks drug access, leadership and 'crazy' co-paysJune 6, 2023 | finance.yahoo.comGBT Received a Notice of Allowance for its Microchip Reliability Verification and Auto-Correction Patent ApplicationJune 4, 2023 | es-us.finanzas.yahoo.comThe Global Non-insulin Diabetes Therapeutics MarketMay 23, 2023 | msn.comPfizer Announces $5.4 Billion Deal to Acquire Global Blood TherapeuticsMay 17, 2023 | marketwatch.com(2023-2030) Anemia Drugs Market Size, Share and Trend Analysis Report, Worldwide Opportunities, Demand ForecastMay 11, 2023 | marketwatch.comArtificial Blood Market, Global Outlook and Forecast 2023-2029May 5, 2023 | marketwatch.com2030 Blood Cancer Therapeutics Market Forecast: Positive Growth Trajectory AheadMay 5, 2023 | finance.yahoo.comRare Disease Therapeutics Global Market Report 2023: Increasing Number of Patients with Rare Diseases Bolsters GrowthMay 5, 2023 | finance.yahoo.comMonoclonal Antibody Therapeutics Market to Surpass US$ 534.26 Billion by 2030, Says Coherent Market Insights (CMI)May 5, 2023 | marketwatch.comMetabolic Disorder Therapeutics Market 2023 Set to Growth Highest CAGR and Revenue by 2030See More Headlines Receive GBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GBT CUSIPN/A CIK1629137 Webwww.gbt.com Phone(650) 741-7700FaxN/AEmployees457Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-303,090,000.00 Net Margins-137.30% Pretax Margin-137.01% Return on Equity-170.37% Return on Assets-39.24% Debt Debt-to-Equity Ratio4.92 Current Ratio6.88 Quick Ratio6.17 Sales & Book Value Annual Sales$194.75 million Price / Sales23.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book22.46Miscellaneous Outstanding Shares67,476,000Free Float64,170,000Market Cap$4.62 billion OptionableOptionable Beta0.45 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Ted W. Love M.D. (Age 63)Pres, CEO & Director Comp: $1.06MMr. Jeffrey S. Farrow (Age 60)CFO & Principal Accounting Officer Comp: $672.67kMs. Jung E. Choi (Age 52)Chief Bus. & Strategy Officer Comp: $645kMr. David L. Johnson (Age 53)Chief Commercial Officer Comp: $661.5kDr. Kim Smith-Whitley M.D. (Age 61)Exec. VP and Head of R&D Comp: $654kDr. David R. PhillipsFounder & AdvisorDr. Matthew P. Jacobson Ph.D.Founder & AdvisorDr. Andrej Sali Ph.D.Founder & AdvisorMs. Nazila Habibizad (Age 59)Exec. VP of Operations Stephanie YaoSr. Director of Corp. Communications & Investor RelationsMore ExecutivesKey CompetitorsOrganon & Co.NYSE:OGNBiohavenNYSE:BHVNAlkermesNASDAQ:ALKSNuvalentNASDAQ:NUVLMadrigal PharmaceuticalsNASDAQ:MDGLView All Competitors GBT Stock Analysis - Frequently Asked Questions How were Global Blood Therapeutics' earnings last quarter? Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced its earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.03. The firm earned $52.05 million during the quarter, compared to the consensus estimate of $53.69 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 170.37% and a negative net margin of 137.30%. The business's revenue was up 41.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.97) EPS. What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO? 20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend. What other stocks do shareholders of Global Blood Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ). When did Global Blood Therapeutics IPO? Global Blood Therapeutics (GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers. This page (NASDAQ:GBT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBill Ackman’s 2024 warningPorter & CompanyWARNING - this content may be disturbingParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Blood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.